Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

(247,360,000) (230,836,000) ------------ ------------ Total stockholders' equity 901,000 15,595,000 ------- ---------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,127,000 $23,057,000 =========== ===========

    PEREGRINE PHARMACEUTICALS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS
    FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2009


                                         2009           2008           2007
                                         ----           ----           ----

    REVENUES:
    Contract manufacturing revenue   $12,963,000     $5,897,000     $3,492,000
    Government contract revenue        5,013,000              -              -
    License revenue                      175,000        196,000        216,000
                                         -------        -------        -------

      Total revenues                  18,151,000      6,093,000      3,708,000

    COSTS AND EXPENSES:
    Cost of contract manufacturing     9,064,000      4,804,000      3,296,000
    Research and development          18,424,000     18,279,000     15,876,000
    Selling, general and
     administrative                    6,979,000      7,150,000      6,446,000
                                       ---------      ---------      ---------

      Total costs and expenses        34,467,000     30,233,000     25,618,000
                                      ----------     ----------     ----------

    LOSS FROM OPERATIONS             (16,316,000)   (24,140,000)  (21,910,000)

    OTHER INCOME (EXPENSE):
    Interest and other income            200,000        989,000      1,160,000
    Interest and other expense          (408,000)       (25,000) 
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 During the ... fresh water supply runs dangerously low, Southern Oregon’s water ... Oregon’s rivers, despite the lowest mountain snow pack on ... late summer and early autumn.* That was the observation ... the new book “Hiking Southern Oregon,” during an interview ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... ... new Seattle based team, Brilliance Weight Loss, has now launched to help take the guesswork and ... products to help people lose weight and gain better health. , ... Seattle, WA (PRWEB) June 17, 2010 -- The battle of lasting ...
... ... to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA in Bayside, ... ... is pleased to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA ...
... ... Garza as an Engineered Sales Representative for Ellsworth Adhesives S. de R.L. de C.V. (Mexico). ... Germantown, WI (PRWEB) ... as an Engineered Sales Representative for Ellsworth Adhesives S. de R.L. de C.V. (Mexico). ...
... is an uncommon benign neoplasm with locally aggressive behavior but ... a 14-year-old patient with clinical presentations of abdominal pain and ... research article to be published on June 7, 2010 in ... A research team led by Professor Ko from Chang Gung ...
... Italy, Thursday 17 June 2010: Biologics-nave Juvenile Idiopathic Arthritis ... compared with the general Swedish population, according to research ... the European League Against Rheumatism in Rome, Italy. Results ... of patients showed an increased frequency of cancer in ...
... ... will be an exciting event for Tosoh Bioscience (Booth #7714) as the company plans to unveil ... HPLC testing. , ... -- The AACC 2010 Annual Meeting in Anaheim, CA will be an exciting event ...
Cached Medicine News:Health News:Brilliance Weight Loss Will Give You the Tools for Effective Weight Loss 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 3Health News:Ellsworth Adhesives Announces New International Engineered Sales Representative 2Health News:Biologics-naive juvenile idiopathic arthritis patients have elevated risk of cancer 2Health News:AACC 2010 Creates Excitement for Tosoh Immunoassay and HPLC Analyzers 2
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Quest Diagnostics ... of diagnostic information services, today announced that its Board ... serve as a director, effective December 1, 2014. Including ... Dr. Leiden is the Chairman, President and CEO of ... years of scientific and commercial experience in the pharmaceutical ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014   ... a world-renowned leader in the field of infertility, ... approach to embryonic screening. The research abstract, released ... for Reproductive Medicine (ASRM) meeting in ... (CCS) and single gene defect (SGD) pre-implantation genetic ...
(Date:10/22/2014)... , October 22, 2014 A ... Gloves Market (Product type, Form, End user, Application and ... Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 ... gloves market. Based on key trends tracked, it is ... at $7.9 billion by 2020, registering a CAGR of ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4
... Kan., Sept. 12 Kansas State,University,s expertise on ... for a prestigious symposium in Kansas City, Mo. ... the Zoonoses and National,Biosecurity Symposium, Monday, Sept. 17, ... City Convention and Entertainment Center, is being,organized by ...
... Alliance for,Hispanic Health (the Alliance) is launching a ... your Hands (Presion alta ... El control esta,en ... of hypertension (high,blood pressure), promoting prevention, and helping ... The Alliance is conducting,education and blood pressure screening ...
Cached Medicine Technology:K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security 2K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security 3Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami 2Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami 3
... Electronic Medical Record system. It stores patient chart ... and everything you would normally put in a ... Someone has to write them, file them, find ... Paper Charts get lost. They find their way ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
... The ORK WAVEFRONT ANALYZER ... the aberrations of the entire ... ability to analyze aberrations in ... of sphere, cylinder, higher order ...
... eye drops quickly remove redness ... other pollutants and provide protection ... and the sun. This unique ... LIQUIFILM®, to soothe, cool and ...
Medicine Products: